The largest database of trusted experimental protocols

52 protocols using cnbr activated sepharose

1

Purification of Human Complement Factor H

Check if the same lab product or an alternative is used in the 5 most similar protocols
Complement factor H was purified from human plasma, as described previously (39 (link)), using an affinity column made up of a monoclonal antibody against human factor H (MRCOX23) coupled to CNBr-activated Sepharose (GE healthcare, UK). Freshly thawed human plasma (Fisher Scientific) was adjusted to 5 mM EDTA, pH 8, and dialyzed overnight against Buffer I (25 mM Tris-HCL, 140 mM NaCl, and 0.5 mM EDTA, pH 7.5). MRCOX23 Sepharose column was washed with three bed volumes of buffer I, and dialyzed plasma was passed through the column. The column was then washed again with the same buffer and factor H was eluted using 3 M MgCl2, pH 6.8. The eluted fractions were dialyzed against H2O overnight, followed by 10 mM potassium phosphate pH 7.4. The samples were then analyzed for purity by 12% v/v SDS-PAGE.
+ Open protocol
+ Expand
2

Polyclonal Antibodies Generation for FBXO47

Check if the same lab product or an alternative is used in the 5 most similar protocols
Polyclonal antibodies against mouse FBXO47 C-terminal (aa272-451) were generated by immunizing rabbits and a guinea pig. FBXO47 middle region (aa174-316) were generated by immunizing a rabbit. His-tagged recombinant proteins of FBXO47 middle region (aa174-316) and C-terminal (aa272-451) were produced by inserting cDNA fragments in-frame with pET19b and pET28c (Novagen) respectively in E. coli strain BL21-CodonPlus (DE3)-RIPL (Agilent), solubilized in a denaturing buffer (6 M HCl-Guanidine, 20 mM Tris-HCl pH 7.5) and purified by Ni-NTA (QIAGEN) under denaturing conditions. The antibodies were affinity-purified from the immunized serum with immobilized antigen peptides on CNBr-activated Sepharose (GE healthcare).
+ Open protocol
+ Expand
3

Purification of Anti-Hi-FGF-2 Antibody

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human Hi-FGF-2 (24 kDa isoform) was cross-linked to CNBr-activated Sepharose (GE Healthcare), as per manufacturer's instructions. The rabbit anti-Hi-FGF-2 antiserum (1 ml) was diluted with 9 ml binding buffer recombinant (40 mM Tris-HCl pH 8.0, 0.2 M NaCl), clarified by filtration, and incubated with human Hi-FGF-2-Sepharose (1 ml slurry) at ambient temperature, with gentle shaking for 2 hours. After extensive washing, bound immunoglobulin (IgG) was eluted with 4 M MgCl2 and dialyzed against 10% glycerol in binding buffer. Pure anti-Hi-FGF-2 IgG was used at 10 µg/ml for immunofluorescence, 20 µg/ml for activity neutralization, and at 1 µg per 100 µg extracted protein for immunoprecipitation.
+ Open protocol
+ Expand
4

Quantitative Biodistribution of ADC Products

Check if the same lab product or an alternative is used in the 5 most similar protocols
The tumor targeting properties of ADC products were assessed by quantitative biodistribution analysis as previously described (24 (link)). Both SIP(F8)-SS-DM1 and IgG(F8)-DM1 were radioiodinated with 125I (PerkinElmer) and chloramine T (Sigma) and purified on a PD-10 column (GE Healthcare). Immunoreactivity of the labeled proteins were confirmed by affinity chromatography, using the recombinant 11-EDA-12 fragment of fibronectin coupled to CNBr-activated Sepharose (GE Healthcare) as previously described (24 (link)). Immunocompetent 129SvEv mice, bearing subcutaneously grafted F9 tumors, were injected into the lateral tail vein at a dose of 5 mg/kg (i.e., 125 μg of ADC per mouse). Groups of mice were sacrificed at different time points (3, 24 and 48 h) after injection. Organs were excised, weighed and radioactivity was measured using a Packard Cobra gamma counter. Biodistribution results were expressed as the percentage of injected activity per gram of tissue [%IA/g +/- standard error of the mean (SEM)].
+ Open protocol
+ Expand
5

Recombinant ZC3H11 Protein Purification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fragments of the ZC3H11 open reading frame (first 104a.a., 119a.a., 136a.a.) were cloned into pQEA38vector after His10-tag, between KpnI and HindIII sites. Bacteria (E.coli strain Rosetta pLysS, Novagen) were grown at room temperature to an OD600 of 0.6, induced with 0.25mM isopropyl β-D-1-thiogalactopyranoside and incubated at the same temperature for five hours before harvesting. Recombinant proteins were purified with Ni-NTA Agarose (QIAGEN) following the manufacturers’ instructions [20 (link)]. Buffer in protein samples was exchanged to PBS. Rabbits were immunized with His10-ZC3H11 (119a.a.) according to standard procedures (Charles River Laboratories, Kisslegg, Germany). Polyclonal antibodies were affinity-purified from crude anti-serum using His10-ZC3H11 (119a.a.) fragment coupled to CNBR-activated Sepharose (GE Healthcare).
+ Open protocol
+ Expand
6

Isolation and Purification of HLA-DR Complexes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peptides were purified as previously described (23 (link), 24 (link)). About 1 × 109 cells were lysed in tris buffer (TB: 50 mM Tris/HCl (pH 7.6), 150 mM NaCl) with 1% Igepal-CA630 supplemented with protease inhibitors (cOmplete Protease Inhibitor Cocktail Tablet, Hoffman-La Roche, Basel, Switzerland) at 4°C for 2 h. Lysates were centrifuged for 10 min at 1,300 × g, and supernatants were ultra-centrifuged for 1 h at 100,000 × g. The soluble fraction was precleared using a Tris-blocked sepharose column (CNBr-activated sepharose, GE Healthcare Bio-Sciences AB, Sweden). The flow-through was incubated overnight at 4°C with B8.11.2-sepharose and washed as follows: first, with 50 ml of TB, 0.5% Igepal-CA630; then, with 200 ml of TB; and, finally, with 500 ml of Tris–HCl pH 7.6, 5 mM NaCl. HLA-DR–peptide complexes were eluted in 0.1% trifluoroacetic acid. Protein-containing fractions were determined by the Bradford method, pooled and concentrated in a SpeedVac (Thermo Fisher scientific, Waltham, MA, USA). Peptides were purified by ultra-filtration in a Centricon-10 device (Millipore, Ireland, Ltd.). Retained material, containing HLA-DRα and β chains are shown in Figure S1 in Supplementary Material.
+ Open protocol
+ Expand
7

In Vitro Stability Evaluation of ADCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
ADCs were incubated at a concentration of 150 μg/mL in mouse serum (Invitrogen) at 37 °C in a shaking incubator. At various time points, aliquots were purified by affinity chromatography onto an antigen-coated resin, based on 11-EDA-12 coupled to CNBr-activated Sepharose (GE Healthcare), washed with PBS and then eluted with 0.1 M glycine solution (pH = 3), prior to analysis by SDS-PAGE and mass spectrometry. In the case of SIP(F8)-SS-DM1, the relative concentration of ADC was assessed by ESI-MS using SIP(F8) coupled to iodoacetamide as internal standard. For IgG(F8)-SS-DM1, the relative ratios of mass spectrometry peak intensity for the unmodified and the drug-modified light chain were used for the quantification of drug release rates [Figure 4].
+ Open protocol
+ Expand
8

Antibody Preparation and Purification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against Opbp [aa 1–331] and CP190 [aa 308–1096] were raised in rats and rabbits and purified from the sera by ammonium sulfate fractionation followed by affinity purification on CNBr-activated Sepharose (GE Healthcare, USA) according to standard protocols. Anti-FLAG M2 antibodies were from Sigma (USA).
+ Open protocol
+ Expand
9

Purification of Complement Component C1q

Check if the same lab product or an alternative is used in the 5 most similar protocols
C1q was purified from freshly thawed plasma, as published earlier (26 (link)). Briefly, plasma was made 5mM EDTA, pH 7.5, and centrifuged at 12,000 × g to remove aggregated lipids. The plasma was then incubated with non-immune IgG coupled to CNBr-activated Sepharose (GE Healthcare, UK) for 1 h at 4°C. The plasma was filtered through a sintered glass funnel, and C1q bound to IgG–Sepharose was then washed extensively with 10 mM HEPES, 140 mM NaCl, 0.5 mM EDTA, and pH 7.0. C1q was eluted with N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) buffer (100 mM CAPS, 1 M NaCl, 0.5 mM EDTA, pH 11). The eluted C1q was then passed through a HiTrap Protein G column (GE Healthcare) to remove IgG contaminants and dialyzed against the washing buffer.
+ Open protocol
+ Expand
10

Rabbit Polyclonal Antibodies for ForA and Rac1A

Check if the same lab product or an alternative is used in the 5 most similar protocols
Polyclonal antibodies against ForA and Rac1A were raised by immunizing a female New Zealand white rabbit with either recombinant GST-tagged ForA-FH3L or GST-tagged Rac1A following standard protocols. Subsequently, the polyclonal antibodies were affinity purified after coupling of the same antigens to CNBr-activated Sepharose (GE Healthcare). Immunoblotting was performed according to standard protocols using undiluted hybridoma supernatants of IQGAP1-specific mAb 216-394-1 (ref. 30 (link), GFP-specific mAb 264-449-2 (ref. 30 (link)), myosin-II-specific mAb 56-396-5 (ref. 64 (link)), Porin-specific mAb 70-100-1 (ref. 65 (link)) or polyclonal anti-Rac1A and anti-ForA antibodies (1:250 dilution). Alexa488-conjugated nanobodies were from Chromotek (1:200 dilution; #gba488) and polyclonal anti-myosin IIA antibodies were from Thermo Scientific (1:100 dilution; #PA5-17025). Primary antibodies in immunoblots were visualized with phosphatase-coupled anti-mouse (1:1,000, #115-055-62; Dianova) or anti-rabbit IgG (1:1,000; #111-055-046; Dianova). Uncropped scans of the most important immunoblots are shown in Supplementary Fig. 6. For immunohistochemistry, secondary Alexa-555-conjugated goat-anti-rabbit polyclonal antibodies (1:1,000 dilution; #A21429; Invitrogen) were used.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!